Bisphosphonates treatment and orthodontic considerations

Orthodontics and Craniofacial Research

Volumn 13, Issue 1, 2010, Pages 1-10

  Ghoneima, A A ^b   Allam, E S ^a   Zunt, S L ^a   Windsor, L J ^a  

^a INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^b Al Azhar University   (Egypt)

Author keywords

Bisphosphonates; Orthodontics; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANIMAL; BONE NECROSIS; BONE REMODELING; CHEMISTRY; DENTAL CARE; DRUG CONTRAINDICATION; DRUG EFFECT; HALF LIFE TIME; HUMAN; JAW; JAW DISEASE; ORAL SURGERY; OSTEOCLAST; PERIODONTAL DISEASE; REVIEW;

ALVEOLAR PROCESS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DENTAL STRESS ANALYSIS; DIPHOSPHONATES; HALF-LIFE; HUMANS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEOCLASTS; OSTEONECROSIS; TOOTH MOVEMENT;

EID: 74049160831     PISSN: 16016335     EISSN: 16016343     Source Type: Journal    
DOI: 10.1111/j.1601-6343.2009.01472.x     Document Type: Review

References (54)

1. Sarathy AP, Bourgeois SL, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two Case Reports. JOE 2005 31 : 759 763.
2. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonates therapy. J Dent Res 2007 86 : 1013 1021.
3. The top 200 brand-name drugs in 2003. Drug Topics 2004 148 : 76.
4. The top 200 brand-name drugs by units in 2006. Available at: http://www.drugtopics.modernmedicine.com (Last accessed 9 April 2009).
5. Lindsay R, Cosman F. Harrison's Principles of Internal Medicine, 15th edn. New York : McGraw-Hill 2001. pp. 2226 2236.
6. Neff MJ. Practical guidelines: ACOG releases guidelines for clinical management of osteoporosis. Am Fam Physician 2004 69 : 1558 1561.
7. Raisz LG. The osteoporosis revolution. Ann Intern Med 1997 126 : 458 462.
8. Berenson JR, Hillner BE, Kyle RA. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002 20 : 3719 3736.
9. Lipton A, Theriault RL, Leff R. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate infusions. Proc Ann Meet Am Soc Clin Oncol 1997 16 : A531.
10. Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer 2005 5 (suppl 2 S54.
11. Marcus R, Wong M, Heath H. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002 23 : 16 37.
12. Brixen K. Bisphosphonates as a potential treatment for osteogenesis imperfecta. Proceedings of the OIFE meeting, September 25-26, 1998. Vingsted, Denmark. Available at: http://www.brandx.net/markgash/bispho.html.
13. Marini JC. Do bisphosphonates make children's bones better or brittle? N Engl J Med 2003 349 : 423 426.
14. Rogers M, Gordon S, Benford H, Coxon F, Luckman S, Monkkonen J et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000 88 : 2961 2978.
15. Roelofs A, Thompson K, Gordon S, Rogers M. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006 20 (Suppl 6222 6230.
16. Boivin G, Meunier P. Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2002 2 : 538 543.
17. Sarin J, DeRossi S, Akintoye S. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008 14 : 277 285.
18. Mackie P, Fisher J, Zhou H, Choong P. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001 84 : 951 958.
19. Lin J. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996 18 : 75 85.
20. Brown J, Neville-Webbe H, Coleman R. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004 11 : 207 224. (Pubitemid 38832826)
21. Fournier P, Boissier S, Filleur S. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 62 : 6538 6544.
22. Lasseter K, Porras A, Denker A. Pharmacokinetic considerations in determining the terminal elimination half lives of bisphosphonates. Clin Drug Invest 2005 25 : 107 114.
23. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 4th edn. San Diego : Academic Press 2000. pp. 40 1.
24. Licata A. Discovery, clinical development, and therapeutic uses of bisphosphonate. Ann Pharmacother 2005 39 : 668 677.
25. Migliorati C. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003 21 : 4253 4254.
26. Hellstein J, Marek C. Bisphosphonate osteonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005 63 : 682 689.
27. Donoghue A. Bisphosphonates and osteonecrosis: analogy to phossy jaw. Med J Aust 2005 183 : 163 164.
28. Starck W, Epker B. Failure of osteointergrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Maxillofac Implants 1995 10 : 74 8.
29. Marx R, Sawatari Y, Fortin M. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005 63 : 1567 1575.
30. Migliorati C, Schubert M, Peterson D, Seneda L. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005 104 : 83 93.
31. FDA Patient Safety News. Show #34, December 2004. Caution on osteonecrosis with bisphosphonates. Available at: http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/psn.
32. Novartis Pharmaceuticals Corporation. Important drug precaution for dental health professionals with patients being treated for cancer [letter to dentists]. Available at: http://www.fda.gov/medwatch/safety/2005/zometa- deardentite-5-5 -05.pdf.
33. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates: a four case report. J Oral Pathol Med 2005 34 : 613 617.
34. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart J. Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 2002 302 : 1055 1061.
35. Marx R, Cillo J, Ulloa J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007 65 : 2397 2410.
36. Edwards B, Hellstein J, Jacobsen P, Kaltman S, Mariotti A, Migliorati C. Updated recommendations for managing the care of patients receiving oral bisphosphonates therapy. An advisory statement from the American Dental Association Council on Scientific Affairs. JADA 2008 139 : 1674 1677.
37. Rinchuse D, Sosovicka M, Robison J, Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 2007 131 : 321 326.
38. Igarashi K, Mltani H, Adachi H, Shinoda H. Anchorage and retentive effects of a bisphosphonates (AHBuBP) on tooth movements in rats. Am J Orthod Dentofacial Orthop 1994 106 : 279 289.
39. Hughes D, MacDonald B, Russell R, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989 83 : 930 935.
40. Schenk R, Merz W, Miuhlbauer R, Russell R, Fleisch H. Effect of ethane-l-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973 11 : 196 214.
41. Rowe D, Hausmann E. The alteration of osteoclast morphology by diphosphonates in bone organ culture. Calcif Tissue Res 1976 20 : 53 60.
42. Plasmans C, Jap P, Kuijpers W, Slooff T. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int 1980 32 : 247 256.
43. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991 88 : 2095 2105.
44. Carano A, Teitelbaum S, Konsek J, Schlesinger P, Blair H. Bisphosphonates directly inhibit the bone resorption. J Clin Invest 1990 85 : 456 461.
45. Bradaschia-Correa V, Massa L, Arana-Chavez V. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res 2007 330 : 475 485.
46. Sato Y, Sakai H, Kobayashi Y, Shibasaki Y, Sasaki T. Bisphosphonate administration alters subcellular localization of vacuolar-type H+ ATPase and Cathepsin K in osteoclasts during experimental movement of rat molars. Anat Rec 2000 260 : 72 80.
47. Schwartz JE. Ask us: some drugs affect tooth movement. Am J Orthod Dentofacial Orthop 2005 127 : 644.
48. Adachi H, Igarashi K, Mitani H, Shinoda H. Effects of topical administration of a bisphosphonate (Risedronate) on orthodontic tooth movements in rats. J Dent Res 1994 73 : 1478 1484.
49. Kim T, Yoshida Y, Yokoya K, Sasaki T. An ultrastructural study of the effects of bisphosphonates administration on osteoclastic bone resorption during relapse of experimentally moved rat molars. Am J Orthod Dentofacial Orthop 1999 115 : 645 653.
50. Liu L, Igarashi K, Haruyama N, Saeki S, Shinoda H, Mitani H. Effects of local administration of clodronate on orthodontic tooth movement and root resorption in rats. Eur J Orthod 2004 26 : 469 473.
51. Igarashi K, Adachi H, Mitani H, Shinodal H. Inhibitory effect of the topical administration of a bisphosphonate (Risedronate) on root resorption incident to orthodontic tooth movement in rats. J Dent Res 1996 75 : 1644 1649.
52. Graham JW. Bisphosphonates and orthodontics: clinical implications. JCO 2006 7 : 425 428.
53. American Dental Association. Report of the Council of Scientific Affairs. Expert panel recommendations: dental management of patients on oral bisphosphonate therapy. Available at: http://www.ada.org/prof/resources/topics/ osteonecrosis.asp [cited 16 March 2009].
54. Zahrowski JJ. Bisphosphonate treatment: a present orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007 131 : 311 320.